Chemotherapy for Carcinoma Gallbladder
For unresectable or metastatic gallbladder carcinoma, the preferred first-line regimen is gemcitabine 1000 mg/m² (days 1,8) plus cisplatin 75 mg/m² (day 1) every 3 weeks, combined with either durvalumab or pembrolizumab immunotherapy. 1
First-Line Treatment (Category 1 Preferred)
The NCCN 2025 guidelines establish two immunotherapy-containing triplet regimens as the current standard of care 1:
Preferred Regimens:
- Gemcitabine 1000 mg/m² IV on days 1 and 8
- Cisplatin 75 mg/m² IV on day 1
- Plus EITHER:
- Durvalumab (checkpoint inhibitor), OR
- Pembrolizumab (checkpoint inhibitor)
- Cycle: Every 21 days
These combinations achieved superior outcomes in phase III trials. The TOPAZ-1 trial demonstrated median OS of 12.9 months with durvalumab/gemcitabine/cisplatin versus 11.3 months with chemotherapy alone (HR 0.76). The KEYNOTE-966 trial showed median OS of 12.7 months with pembrolizumab/gemcitabine/cisplatin versus 10.9 months with chemotherapy alone (HR 0.83) 1.
If Cisplatin-Ineligible:
Substitute carboplatin for cisplatin in the above regimens 1.
Chemotherapy Doublet (When Immunotherapy Unavailable):
If immunotherapy is not accessible, gemcitabine 1000 mg/m² (days 1,8) plus cisplatin 75 mg/m² (day 1) every 3 weeks remains an acceptable option 1, 2. This doublet achieved ORR of 63.5% and median OS of 11.0 months in recent prospective data from high-incidence regions 2.
Alternative First-Line Options
While not preferred, other regimens with supporting evidence include:
Gemcitabine plus nab-paclitaxel: Gemcitabine 1000 mg/m² plus nab-paclitaxel 125 mg/m² (days 1,8) every 21 days showed ORR of 48.4% and median OS of 20.9 months in unresectable gallbladder cancer 3
Triplet with nab-paclitaxel: Adding nab-paclitaxel to gemcitabine/cisplatin improved ORR to 61.9% versus 13.3% with doublet alone, though this requires validation 4
Treatment Duration and Monitoring
- Continue until disease progression or unacceptable toxicity
- Typical duration: Up to 6 cycles for chemotherapy component 1, 2
- Reassess every 2-3 cycles using RECIST 1.1 criteria 2
Common Toxicities and Management
The most frequent grade 3-4 adverse events with gemcitabine/cisplatin/immunotherapy combinations include 1:
- Neutropenia (19-27%) - most common hematologic toxicity
- Anemia (19%)
- Decreased neutrophil count (21-25%)
With gemcitabine/cisplatin doublet alone 2:
- Neutropenia (any grade 73%, grade 3-4: 27%)
- G-CSF support required in approximately 41% of patients
- Non-hematological adverse events typically mild-to-moderate
Critical caveat: Concurrent gemcitabine with radiation is NOT recommended due to excessive toxicity 1.
Subsequent-Line Therapy
For progressive disease after first-line treatment, options depend on prior therapy and molecular profiling 1:
- If checkpoint inhibitor-naive: Consider durvalumab/gemcitabine/cisplatin or pembrolizumab/gemcitabine/cisplatin
- Targeted therapies for specific mutations (FGFR2, IDH1, HER2, NTRK, RET, BRAF, KRAS G12C)
- Regorafenib (category 2B): Median PFS 3.0 months versus 1.5 months with placebo 1
Special Populations
Recurrent disease >6 months after curative surgery: Treat as first-line metastatic disease with immunotherapy-containing regimens 1.
Resected disease with positive margins (R1) or positive nodes: Preferred approach is systemic therapy with capecitabine monotherapy (category 1) for up to 6 months, or gemcitabine-based regimens 1.